• Cell Senescence β-Galactosidase Kit: Evidence Scope

  2026-10-14

  The Cell Senescence β-Galactosidase Staining Kit (K2185) is described by APExBIO as an X-gal-based assay for detecting senescence-associated β-galactosidase activity in cells and frozen tissue sections. The supplied documentation supports a measurement-principle overview, but not independent claims about analytical performance, specificity across biological models, or validated research outcomes.

• JEV, NS4B and Lysosomal Dysfunction

  2026-10-14

  A source-grounded overview of a 2024 Veterinary Microbiology study linking Japanese encephalitis virus NS4B with ER-stress-associated autophagy, reduced LAMP1/LAMP2, impaired lysosomal function and abnormal SLA-DR aggregation. The findings are mechanistically suggestive but remain bounded by the study’s cellular context and the absence of evidence for clinical or therapeutic effects.

• TCAIM Reveals a New Layer of Mitochondrial Control

  2026-10-13

  A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that binds native OGDH and promotes its reduction through HSPA9 and LONP1. The findings connect mitochondrial proteostasis with control of carbohydrate catabolism, while leaving the direct role of ATP and the broader applicability of the mechanism unresolved.

• Sulfo-Cy3 Azide in Neurodevelopmental Imaging

  2026-10-13

  Sulfo-Cy3 azide is a supplier-described water-soluble bioconjugation reagent for fluorescent labeling, while rat claustrum research provides a biological context in which molecular markers and developmental timing can be interpreted. The available evidence supports conceptual relevance, not a direct claim that this product was used in the cited study or that its performance has been independently established in that model.

• Melatonin and Hypertrophic Scar: What the Study Shows

  2026-10-12

  A preclinical study examined whether melatonin suppresses hypertrophic-scar fibroblast activity through MT2-linked PI3K/Akt/mTOR signaling and autophagy. Its findings support an antifibrotic association, but the evidence remains limited by model choice, incomplete quantitative reporting in the supplied record, and the indirect nature of pathway and oxidative-stress measurements.

• AT13387 and Norovirus Study: Evidence Boundaries

  2026-10-12

  AT13387 is described by APExBIO as an Hsp90 inhibitor for cancer biology research, whereas the supplied 2025 norovirus study investigates NINJ1-dependent secretion and caspase-3 activity in murine norovirus infection. The sources do not establish that AT13387 affects norovirus, NINJ1, or viral protein secretion.

• Gap26 and 3D Osteocyte Calcium Signaling

  2026-10-11

  Gap26 is a connexin 43 mimetic peptide with potential value for interpreting calcium signaling in mechanically stimulated 3D osteocyte networks. This evidence-focused analysis connects the peptide’s reported mechanism with a 2025 microfluidic osteocyte model while clarifying what remains unvalidated.

• Triacetin in Biomedical Research: Evidence and Limits

  2026-10-10

  Triacetin, also called glyceryl triacetate, appears in biomedical research as a formulation excipient, lipid-related biochemical reagent, and subject of exploratory metabolic and cancer studies. The strongest supplied evidence concerns brinzolamide nanoemulsions, where Triacetin was evaluated among several excipients in ocular safety and permeation tests. Claims involving glioblastoma, HDAC signaling, AMPK, and anti-obesity effects remain preliminary because the supplied materials do not include complete primary-study citations or clinical evidence.

• Small Molecules Improve Pancreatic Ductal Organoids

  2026-10-09

  Liao and colleagues describe a small-molecule culture strategy that improves the initiation and expansion of pancreatic ductal organoids while retaining heterogeneous ductal and acinar features. The study provides a more scalable conceptual platform for pancreatic disease modeling and drug-screening research, although the supplied report does not establish how each compound contributes to the phenotype.

• β-Elemene Inhibits Adipogenesis via AMPK

  2026-10-09

  A 2025 study reports that β-Elemene reduces differentiation-associated lipid accumulation and improves glucose handling in 3T3-L1 cellular models, with AMPK signaling identified as a responsive pathway. The work provides a mechanistic starting point for metabolic research, but its findings remain limited to an in vitro mouse preadipocyte system and do not establish efficacy in obesity, diabetes, or human disease.

• CS18, TopBP1, and Therapeutic Resistance

  2026-10-08

  Lin and colleagues report CS18, a structurally distinct inhibitor of the TopBP1 BRCT7/8 domains that disrupts oncogenic protein interactions without directly interfering with DNA replication. The study links CS18 to MYC suppression, E2F1-dependent apoptosis, PARP inhibitor sensitization, and restored osimertinib response in preclinical cancer models.

• Ibuprofen in Research: Evidence and Limits

  2026-10-08

  A source-grounded overview of Ibuprofen research, covering COX biology, cancer and pain models, conceptual applications, evidence quality, protein-binding context, and limits on interpreting vendor-reported findings.

• Streptavidin-FITC and PFOS Sertoli Cell Research

  2026-10-07

  A source-grounded overview of PFOS-related Sertoli-cell injury, the ATF2/WT1 mitochondrial mechanism, and the conceptual role and limits of Streptavidin-FITC detection.

• Human iPSC Sensory Neurons Model HSV-1 Latency

  2026-10-07

  Oh et al. developed and validated a scalable human induced pluripotent stem cell-derived sensory neuron model for studying HSV-1 latency and reactivation. The model combines neuronal functional validation with virological, transcriptional, and chromatin-based evidence, offering a human-relevant complement to animal systems while retaining important in vitro limitations.

• SB 431542 in TGF-β and Intestinal Research

  2026-10-06

  SB 431542 is an ALK5 inhibitor used to investigate TGF-β signaling. In a mouse study of intestinal MOB1A/B depletion, pharmacologic pathway inhibition partially restored epithelial differentiation but did not recover intestinal stem-cell pools, highlighting both the value and limits of pathway-level interpretation.

8092 records 1/540 page Next 12345 下5页 Last page